The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review

Cancer Treatment Reviews

Volumn 35, Issue 5, 2009, Pages 425-430

  Röllig, Christoph ^a   Illmer, Thomas ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Arsenic; ATO; Efficacy; Multiple myeloma; Plasmacytoma; Refractory; Relapsed; Systematic review

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; MULTIPLE MYELOMA; OVERALL SURVIVAL; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ARSENICALS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OXIDES; TREATMENT OUTCOME;

EID: 67849084851     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.04.007     Document Type: Review

References (38)

1. Munshi N.C. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 6 Suppl. 2 (2001) 17-21
2. Anderson K.C., Boise L.H., Louie R., and Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8 (2002) 12-25
3. Dilda P.J., and Hogg P.J. Arsenical-based cancer drugs. Cancer Treat Rev 33 (2007) 542-564
4. Rousselot P., Arnulf B., Poupon J., et al. Phase I/II study of arsenic trioxide in the treatment of refractory multiple myeloma. Blood 102 (2003) 380B-381B
5. Salmon S.E., Durie B.G., and Hamburger A.W. A new basis for treatment of multiple myeloma. Schweiz Med Wochenschr 108 (1978) 1568-1572
6. Downs S.H., and Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52 (1998) 377-384
7. Scottish Intercollegiate Guidelines Network. SIGN 50. A guideline developer's handbook. Edinburgh; 2008.
8. Berenson J.R., Matous J., Ferretti D., et al. A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma. Blood 106 (2005) 721A
9. Berenson J.R., Boccia R., Siegel D., et al. A multicenter phase II study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) for patients with relapsed or refractory multiple myeloma. Blood 106 (2005) 720A-721A
10. Berenson J.R., Matous J., Ferretti D., et al. A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma. J Clin Oncol 24 (2006) 7611
11. Qazilbash M.H., Davis M.S., Ana A., et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: A new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma. Blood 106 (2005) 338A-339A
12. Qazilbash M.H., Jindani S., Gul Z., et al. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 13 (2007) 9S-10S
13. Wu K.L., van D.J., Beksac M., de Knegt V., and Sonneveld P. Treatment with arsenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: preliminary findings of a multicenter, phase II study. Blood 106 (2005) 367B
14. Qazilbash M.H., Saliba R., Parikh G., et al. Arsenic trioxide with ascorbic acid and high-dose melphalan is safe and effective for autotransplantation for multiple myeloma. Blood 110 (2007) 942
15. Hofmeister C.C., Jansak B., Denlinger N., et al. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res 32 (2008) 1295-1298
16. Baz R., Kelly M., Reed J., et al. Phase II study of dexamethasone, ascorbic acid, thalidomide and arsenic trioxide (DATA) in high risk previously untreated (PU) and relapsed/refractory (RR) multiple myeloma (MM). J Clin Oncol 24 (2006) 17535
17. Berenson J.R. A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) in patients with relapsed or refractory multiple myeloma. Blood 104 (2004) 659A
18. Gesundheit B., Shapira M.Y., Resnick I., et al. Trisenox (arsenic trioxide) in the treatment for multiple myeloma after bone marrow transplantation. Blood 106 (2005) 365B
19. Bahlis N.J., Cafferty-Grad J., Jordan-McMurry I., et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8 (2002) 3658-3668
20. Birch R., Schwartzberg L.S., Schnell F.M., Tongol J.M., and Prill S.J. A phase II study of arsenic trioxide (ATO) in combination with dexamethasone (Dex) and ascorbic acid (VITC) in patients with relapsed/refractory multiple myeloma. Blood 102 (2003) 386B
21. Borad M.J., Swift R., and Berenson J.R. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 19 (2005) 154-156
22. Dey S., Gupta P., Chitalkar P.G., and Mukhopadhyay A. Arsenic trioxide for treatment of multiple myeloma. Ann Oncol 18 (2007) ix178-ix182
23. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16 (2002) 1835-1837
24. Rousselot P., Larghero J., Arnulf B., et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 18 (2004) 1518-1521
25. Berenson J.R., Matous J., Swift R.A., et al. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (2007) 1762-1768
26. Hussein M.A., Saleh M., Ravandi F., et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125 (2004) 470-476
27. Berenson J.R., Boccia R., Siegel D., et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2006) 174-183
28. Abou-Jawde R.M., Reed J., Kelly M., et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2006) 263-272
29. Wu K.L., Beksac M., van D.J., et al. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 91 (2006) 1722-1723
30. Rajkumar S.V., and Greipp P.R. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 13 (1999) 1295-1314 xi
31. Wen J., Cheng H.Y., Feng Y., et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140 (2008) 169-180
32. Lunghi P., Giuliani N., Mazzera L., et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112 (2008) 2450-2462
33. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
34. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110 (2007) 3557-3560
35. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
36. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
37. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
38. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142